Drug Profile
Research programme: companion diagnostics - Astellas Pharma/QIAGEN
Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator QIAGEN
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for research development in Cancer(Diagnosis) in Netherlands
- 28 Oct 2014 Astellas Pharma and QIAGEN collaborate to develop and commercialise companion diagnostics for Astellas' compounds
- 28 Oct 2014 Early research in Cancer (Diagnosis) in Netherlands (unspecified route)